Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-01-07

Clinical Trial Update: A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia [Phase 2]

View source ↗

Summary

Phase 2 trial update for AGN-214868 in postherpetic neuralgia; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AGN-214868

Snippet

Sponsor: Allergan | Conditions: Neuralgia, Postherpetic | Phase 2 | Status: TERMINATED | Results posted: 2020-01-07